U.S., Europe Pharmas Plan To Increase Japanese Presence
This article was originally published in PharmAsia News
Executive Summary
Drug makers in the United States and Europe are shifting to Japan's pharmaceutical market for sales seen as more lucrative than their home business. Boehringer Ingelheim of Germany plans an increase in its Japanese medical representatives by as much as half by 2012 and Swiss maker Novartis plans to hire 100 in the next fiscal year. Pfizer of the United States plans to release 30 new drugs in Japan by 2012, all of the plans contributing to a forecast growth of as much as 5 percent. That is a percentage point better than the growth expected in five European nations and more than double that of the U.S. market. (Click here for more - a subscription may be required
You may also be interested in...
Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus
Novartis Japanese subsidiary Novartis Pharma KK announced Jan. 21 four new drug approvals from Japan's Ministry of Health, Labor and Welfare. The new drugs are approved to treat asthma, hypertension, cancer and age-related macular degeneration
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.